Azarova, Anna M., Gargi Gautam, and Rani E. George. ‘Emerging Importance of ALK in Neuroblastoma’. Seminars in Cancer Biology 21.4 (2011): 267–275. Web.
Beierle, Elizabeth A. ‘MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK)’. Frontiers in bioscience (Elite edition) 3 n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>.
Bell, Emma et al. ‘MYCN Oncoprotein Targets and Their Therapeutic Potential’. Cancer Letters 293.2 (2010): 144–157. Web.
Bender, Sebastian et al. ‘Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas’. Cancer Cell 24.5 (2013): 660–672. Web.
Berry, Teeara et al. ‘The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma’. Cancer Cell 22.1 (2012): 117–130. Web.
Bleggi-Torres, Luiz Fernando et al. ‘Accuracy of the Smear Technique in the Cytological Diagnosis of 650 Lesions of the Central Nervous System’. Diagnostic Cytopathology 24.4 (2001): 293–295. Web.
Blümcke, Ingmar et al. ‘Low-Grade Epilepsy-Associated Neuroepithelial Tumours — the 2016 WHO Classification’. Nature Reviews Neurology 12.12 (2016): 732–740. Web.
Brodeur, Garrett M. ‘Neuroblastoma: Biological Insights into a Clinical Enigma’. Nature Reviews Cancer 3.3 (2003): 203–216. Web.
Brodeur, Garrett M., and Rochelle Bagatell. ‘Mechanisms of Neuroblastoma Regression’. Nature Reviews Clinical Oncology 11.12 (2014): 704–713. Web.
Brown, Christine E. et al. ‘Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy’. New England Journal of Medicine 375.26 (2016): 2561–2569. Web.
Buckner, Tyler, Julie Blatt, and Scott Victor Smith. ‘The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience’. Pediatric and Developmental Pathology 9.5 (2006): 374–380. Web.
Burkhart, C. A. et al. ‘Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma’. JNCI Journal of the National Cancer Institute 95.18 (2003): 1394–1403. Web.
Chen, L. et al. ‘P53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma’. Cancer Research 70.4 (2010): 1377–1388. Web.
Chhabda, Sahil et al. ‘The 2016 World Health Organization Classification of Tumours of the Central Nervous System: What the Paediatric Neuroradiologist Needs to Know’. Quantitative Imaging in Medicine and Surgery 6.5 (2016): 486–489. Web.
‘Children’s Cancer Statistics | Cancer Research UK’. N.p., n.d. Web. <http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>.
Cossu, Irene et al. ‘Neuroblastoma-Targeted Nanocarriers Improve Drug Delivery and Penetration, Delay Tumor Growth and Abrogate Metastatic Diffusion’. Biomaterials 68 (2015): 89–99. Web.
Ellison, David W. et al. ‘β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children’s Cancer Study Group Brain Tumour Committee’. Journal of Clinical Oncology 23.31 (2005): 7951–7957. Web.
Evans, A E, E Baum, and R Chard. ‘Do Infants with Stage IV-S Neuroblastoma Need Treatment?’ Archives of Disease in Childhood 56.4 (1981): 271–274. Web.
Fisher, Jonathan et al. ‘Avoidance of On-Target Off-Tumor Activation Using a Co-Stimulation-Only Chimeric Antigen Receptor’. Molecular Therapy 25.5 (2017): 1234–1247. Web.
Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. ‘Amplification of N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage’. Science 224.4653 (1984): 1121–1124. Web. <http://www.jstor.org/stable/1692440>.
Ghorashian, Sara, Persis Amrolia, and Paul Veys. ‘Open Access? Widening Access to Chimeric Antigen Receptor (CAR) Therapy for ALL’. Experimental Hematology 66 (2018): 5–16. Web.
Gibson, Paul et al. ‘Subtypes of Medulloblastoma Have Distinct Developmental Origins’. Nature 468.7327 (2010): 1095–1099. Web.
Goschzik, Tobias et al. ‘Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma’. Journal of Neuropathology & Experimental Neurology (2017): n. pag. Web.
Greaves, Mel F., and Joe Wiemels. ‘Origins of Chromosome Translocations in Childhood Leukaemia’. Nature Reviews Cancer 3.9 (2003): 639–649. Web.
Guglielmi, L et al. ‘MYCN Gene Expression Is Required for the Onset of the Differentiation Programme in Neuroblastoma Cells’. Cell Death & Disease 5.2 (2014): e1081–e1081. Web.
Gump, Jacob M et al. ‘Identification of Targets for Rational Pharmacological Therapy in Childhood Craniopharyngioma’. Acta Neuropathologica Communications 3.1 (2015): n. pag. Web.
Hanahan, Douglas, and Robert A Weinberg. ‘The Hallmarks of Cancer’. Cell 100.1 (2000): 57–70. Web.
Hanahan, Douglas, and Robert A. Weinberg. ‘Hallmarks of Cancer: The Next Generation’. Cell 144.5 (2011): 646–674. Web.
Hashizume, Rintaro et al. ‘Pharmacologic Inhibition of Histone Demethylation as a Therapy for Pediatric Brainstem Glioma’. Nature Medicine 20.12 (2014): 1394–1396. Web.
Hasle, Henrik, and Charlotte M. Niemeyer. ‘Advances in the Prognostication and Management of Advanced MDS in Children’. British Journal of Haematology 154.2 (2011): 185–195. Web.
Hill, Rebecca M. et al. ‘Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease’. Cancer Cell 27.1 (2015): 72–84. Web.
Hourigan, Christopher S., and Judith E. Karp. ‘Minimal Residual Disease in Acute Myeloid Leukaemia’. Nature Reviews Clinical Oncology 10.8 (2013): 460–471. Web.
Huang, M., and W. A. Weiss. ‘Neuroblastoma and MYCN’. Cold Spring Harbor Perspectives in Medicine 3.10 (2013): a014415–a014415. Web.
Huber, Katrin, Chaya Kalcheim, and Klaus Unsicker. ‘The Development of the Chromaffin Cell Lineage from the Neural Crest’. Autonomic Neuroscience 151.1 (2009): 10–16. Web.
Hubert, Christopher G. et al. ‘A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found’. Cancer Research 76.8 (2016): 2465–2477. Web.
Hunger, Stephen P., and Charles G. Mullighan. ‘Acute Lymphoblastic Leukemia in Children’. New England Journal of Medicine 373.16 (2015): 1541–1552. Web.
International Agency for Research on Cancer. WHO Classification of Tumours of the Central Nervous System. Ed. David N. Louis et al. Revised 4th edition. Lyon: International Agency for Research on Cancer, 2016. Print.
Johnson, Laura A, and Carl H June. ‘Driving Gene-Engineered T Cell Immunotherapy of Cancer’. Cell Research 27.1 (2017): 38–58. Web.
Kirsti Sirkiä, Ulla M. Saarinen‐Pihkala, Liisa Hovi, Hannu Sariola. ‘Autopsy in Children with Cancer Who Die While in Terminal Care’. Medical and Pediatric Oncology 30.5 (1998): 284–289. Web. <https://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1096-911X(199805)30:5%3C284::AID-MPO4%3E3.0.CO;2-B>.
Klebanoff, Christopher A, Steven A Rosenberg, and Nicholas P Restifo. ‘Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers’. Nature Medicine 22.1 (2016): 26–36. Web.
Koebel, Catherine M. et al. ‘Adaptive Immunity Maintains Occult Cancer in an Equilibrium State’. Nature 450.7171 (2007): 903–907. Web.
Korshunov, AndreySturm, DominikRyzhova, MarinaHovestadt, VolkerGessi, Marco. ‘Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma, and Medulloepithelioma Share Molecular Similarity and Comprise a Single Clinicopathological Entity’. Acta Neuropathologica 128.8 279–89. Web. <https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&accountid=14511>.
Kotrova, Michaela et al. ‘Is Next-Generation Sequencing the Way to Go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?’ Molecular Diagnosis & Therapy 21.5 (2017): 481–492. Web.
Larson, Jon D. et al. ‘Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression’. Cancer Cell (2018): n. pag. Web.
Lee, Tong Ihn, and Richard A. Young. ‘Transcriptional Regulation and Its Misregulation in Disease’. Cell 152.6 (2013): 1237–1251. Web.
Lewis, P. W. et al. ‘Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma’. Science 340.6134 (2013): 857–861. Web.
Liu, Zhihui, and Carol J. Thiele. ‘ALK and MYCN: When Two Oncogenes Are Better than One’. Cancer Cell 21.3 (2012): 325–326. Web.
Lord, Christopher J, and Alan Ashworth. ‘Biology-Driven Cancer Drug Development: Back to the Future’. BMC Biology 8.1 (2010): n. pag. Web.
Lu, Benjamin et al. ‘Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials’. Cancers 8.9 (2016): n. pag. Web.
Mackall, Crystal L., Melinda S. Merchant, and Terry J. Fry. ‘Immune-Based Therapies for Childhood Cancer’. Nature Reviews Clinical Oncology 11.12 (2014): 693–703. Web.
Majzner, Robbie G., Sabine Heitzeneder, and Crystal L. Mackall. ‘Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers’. Cancer Cell 31.4 (2017): 476–485. Web.
Marabelle, Aurélien et al. ‘Hypercalcemia and 13- -Retinoic Acid in Post-Consolidation Therapy of Neuroblastoma’. Pediatric Blood & Cancer 52.2 (2009): 280–283. Web.
Martinez-Barbera, Juan Pedro, and Cynthia L. Andoniadou. ‘Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma’. STEM CELLS 34.2 (2016): 268–276. Web.
Martinez-Barbera, Juan Pedro, and Rolf Buslei. ‘Adamantinomatous Craniopharyngioma: Pathology, Molecular Genetics and Mouse Models’. Journal of Pediatric Endocrinology and Metabolism 28.1–2 (2015): n. pag. Web.
Matthay, Katherine K. et al. ‘Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13- -Retinoic Acid’. New England Journal of Medicine 341.16 (1999): 1165–1173. Web.
Milne, Thomas A. ‘Mouse Models of MLL Leukemia: Recapitulating the Human Disease’. Blood 129.16 (2017): 2217–2223. Web.
Morsut, Leonardo et al. ‘Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors’. Cell 164.4 (2016): 780–791. Web.
Mossé, Yaël P. et al. ‘Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene’. Nature 455.7215 (2008): 930–935. Web.
Nataliya Zhukova. ‘Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma’. Journal of Clinical Oncology 31.23 (2013): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878050/>.
‘Nature Reviews Immunology’. 12.4 (2012): n. pag. Web. <https://www.nature.com/nri/volumes/12/issues/4>.
Niemeyer, Charlotte Marie, and Christian Peter Kratz. ‘Paediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukaemia: Molecular Classification and Treatment Options’. British Journal of Haematology 140.6 (2008): 610–624. Web.
Niklison-Chirou, Maria Victoria et al. ‘TAp73 Is a Marker of Glutamine Addiction in Medulloblastoma’. Genes & Development 31.17 (2017): 1738–1753. Web.
Northcott, Paul A. et al. ‘The Clinical Implications of Medulloblastoma Subgroups’. Nature Reviews Neurology 8.6 (2012): 340–351. Web.
O’Connor, David et al. ‘Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia’. Journal of Clinical Oncology 36.1 (2018): 34–43. Web.
---. ‘Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia’. Journal of Clinical Oncology 36.1 (2018): 34–43. Web.
Pastorino, Fabio et al. ‘Ligand-Targeted Liposomal Therapies of Neuroblastoma’. Current Medicinal Chemistry 14.29 (2007): 3070–3078. Web.
Pathania, Manav et al. ‘H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas’. Cancer Cell 32.5 (2017): 684-700.e9. Web.
Pfister, Stefan et al. ‘Novel Genomic Amplification Targeting the microRNA Cluster at 19q13.42 in a Pediatric Embryonal Tumor with Abundant Neuropil and True Rosettes’. Acta Neuropathologica 117.4 (2009): 457–464. Web.
Phoenix, Timothy N. et al. ‘Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype’. Cancer Cell 29.4 (2016): 508–522. Web.
Qasim, Waseem et al. ‘Molecular Remission of Infant B-ALL after Infusion of Universal TALEN Gene-Edited CAR T Cells’. Science Translational Medicine 9.374 (2017): n. pag. Web.
Qiao, Jingbo et al. ‘PI3K/AKT and ERK Regulate Retinoic Acid-Induced Neuroblastoma Cellular Differentiation’. Biochemical and Biophysical Research Communications 424.3 (2012): 421–426. Web.
Rasaiyaah, Jane et al. ‘TCRαβ/CD3 Disruption Enables CD3-Specific Antileukemic T Cell Immunotherapy’. JCI Insight 3.13 (2018): n. pag. Web.
Reynolds, C.Patrick et al. ‘Retinoid Therapy of High-Risk Neuroblastoma’. Cancer Letters 197.1–2 (2003): 185–192. Web.
Richmond, A., and Y. Su. ‘Mouse Xenograft Models vs GEM Models for Human Cancer Therapeutics’. Disease Models and Mechanisms 1.2–3 (2008): 78–82. Web.
Sadelain, Michel, Isabelle Rivière, and Stanley Riddell. ‘Therapeutic T Cell Engineering’. Nature 545.7655 (2017): 423–431. Web.
Schwab, M. ‘MYCN in Neuronal Tumours’. Cancer Letters 204.2 (2004): 179–187. Web.
Schwalbe, Ed. C. et al. ‘Histologically Defined Central Nervous System Primitive Neuro-Ectodermal Tumours (CNS-PNETs) Display Heterogeneous DNA Methylation Profiles and Show Relationships to Other Paediatric Brain Tumour Types’. Acta Neuropathologica 126.6 (2013): 943–946. Web.
Schwalbe, Edward C et al. ‘Novel Molecular Subgroups for Clinical Classification and Outcome Prediction in Childhood Medulloblastoma: A Cohort Study’. The Lancet Oncology 18.7 (2017): 958–971. Web.
Schwartzentruber, Jeremy et al. ‘Driver Mutations in Histone H3.3 and Chromatin Remodelling Genes in Paediatric Glioblastoma’. Nature 482.7384 (2012): 226–231. Web.
Sidell, Neil. ‘Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro’. JNCI: Journal of the National Cancer Institute (1982): n. pag. Web.
Slany, R K. ‘The Molecular Mechanics of Mixed Lineage Leukemia’. Oncogene 35.40 (2016): 5215–5223. Web.
Stone, T. J., and T. S. Jacques. ‘Medulloblastoma: Selecting Children for Reduced Treatment’. Neuropathology and Applied Neurobiology 41.2 (2015): 106–108. Web.
Strebhardt, Klaus, and Axel Ullrich. ‘Paul Ehrlich’s Magic Bullet Concept: 100 Years of Progress’. Nature Reviews Cancer 8.6 (2008): 473–480. Web.
Sturm, Dominik, Hendrik Witt, et al. ‘Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma’. Cancer Cell 22.4 (2012): 425–437. Web.
Sturm, Dominik, Brent A. Orr, et al. ‘New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs’. Cell 164.5 (2016): 1060–1072. Web.
Taylor, Michael DNorthcott, Paul AKorshunov, AndreyRemke, MarcCho, Yoon-jae. ‘Molecular Subgroups of Medulloblastoma: The Current Consensus’. Acta Neuropathologica 123.3 465–72. Web. <https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo>.
Vogelstein, B. et al. ‘Cancer Genome Landscapes’. Science 339.6127 (2013): 1546–1558. Web.
---. ‘Cancer Genome Landscapes’. Science 339.6127 (2013): 1546–1558. Web.
Vora, Ajay, Nick Goulden, Chris Mitchell, et al. ‘Augmented Post-Remission Therapy for a Minimal Residual Disease-Defined High-Risk Subgroup of Children and Young People with Clinical Standard-Risk and Intermediate-Risk Acute Lymphoblastic Leukaemia (UKALL 2003): A Randomised Controlled Trial’. The Lancet Oncology 15.8 (2014): 809–818. Web.
Vora, Ajay, Nick Goulden, Rachel Wade, et al. ‘Treatment Reduction for Children and Young Adults with Low-Risk Acute Lymphoblastic Leukaemia Defined by Minimal Residual Disease (UKALL 2003): A Randomised Controlled Trial’. The Lancet Oncology 14.3 (2013): 199–209. Web.
Wegman-Ostrosky, Talia, and Sharon A. Savage. ‘The Genomics of Inherited Bone Marrow Failure: From Mechanism to the Clinic’. British Journal of Haematology 177.4 (2017): 526–542. Web.
Weinberg, Robert A. The Biology of Cancer. 2nd ed. New York: Garland Science, 2014. Print.
Wright, James Homer. ‘NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED’. The Journal of Experimental Medicine 12.4 (1910): n. pag. Web.
Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing. ‘PHOX2B Is Associated with Neuroblastoma Cell Differentiation’. Cancer Biotherapy & Radiopharmaceuticals 31 44–51. Web. <https://search.proquest.com/docview/1776665507?rfr_id=info%3Axri%2Fsid%3Aprimo>.
Yong, Carmen S M et al. ‘CAR T-Cell Therapy of Solid Tumors’. Immunology and Cell Biology 95.4 (2017): 356–363. Web.
Zelent, Arthur, Mel Greaves, and Tariq Enver. ‘Role of the TEL-AML1 Fusion Gene in the Molecular Pathogenesis of Childhood Acute Lymphoblastic Leukaemia’. Oncogene 23.24 (2004): 4275–4283. Web.
Zhu, Shizhen et al. ‘Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis’. Cancer Cell 21.3 (2012): 362–373. Web.
